Bintrafusp alfa versus pembrolizumab in patients with treatment-naive, PD-L1-high advanced non-small cell lung cancer: a randomized, open-label, phase 3 trial

By sjmartinez • August 20, 2023

Cho BC, Lee JS, Wu YL, Cicin I, Dols MC, Ahn MJ, Cuppens K, Veillon R, Nadal E, Dias JM, Martin C, Reck M, Garon EB, Felip E, Paz-Ares L, Mornex F, Vokes EE, Adjei AA, Robinson C, Sato M, Vugmeyster Y, Machl A, Audhuy F, Chaudhary S, Barlesi F. Bintrafusp alfa versus pembrolizumab in patients with treatment-naive, PD-L1-high advanced non-small cell lung cancer: a randomized, open-label, phase 3 trial. J Thorac Oncol. 2023 Aug 17:S1556-0864(23)00738-4. doi: 10.1016/j.jtho.2023.08.018. Epub ahead of print. PMID: 37597750.

Tags: bintrafusp alfa, Hematology/Oncology, Non-small cell lung cancer, PD-L1, phase 3, Publications

TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer

Okamoto I, Kuyama S, Girard N, Lu S, Franke F, Li Z, Danchaivijitr P, Han JY, Sun JM, Sugawara S, Pan E, Ren N, Chen[...]

Insurance remains a major source of disparity for patients with testicular cancer: call for advocacy

Starr S, Zhang J, Lin L, Shen J, Gamalong G, Litwin MS, Drakaki A, Chamie K. Insurance remains a major source of disparity for patients[...]

NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3

Wainberg ZA, M O'Reilly E. NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3. Nat Rev Clin Oncol. 2024 Oct 25. doi: 10.1038/s41571-024-00952-5.[...]